Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Radiol ; 60(6): 702-709, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30205701

RESUMO

BACKGROUND: Treatment outcome for hepatocellular carcinoma (HCC) is related to tumor burden and liver function. Grading systems assessing liver function need validation in different clinical settings. PURPOSE: To evaluate drug-eluting embolic transarterial chemoembolization (DEE-TACE) in Child-Pugh A HCC with respect to albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (P-ALBI) grade. MATERIAL AND METHODS: Forty-nine patients with Child-Pugh class A, diagnosed with HCC and allocated to DEE-TACE treatment, were retrospectively analyzed regarding tumor and treatment characteristics, radiological response (mRECIST) one month post treatment, overall survival (OS), and adverse events (AEs; CTCAE, grades ≥3) with respect to ALBI and P-ALBI grade. RESULTS: There were 21 ALBI 1 patients, 29 P-ALBI 1 patients, and 19 patients were both ALBI and P-ALBI 1. Objective response rate was 74% with no statistically significant difference for ALBI (1 vs. 2; P = 0.08), or P-ALBI (1 vs. 2; P = 0.49). OS was 14.8 months (range = 1.7-62.0; ALBI 1 vs. 2: P = 0.08; P-ALBI 1 vs. 2: P = 0.003). OS in responders with ALBI 1 and 2 was 28.9 vs.10.2 months ( P = 0.02), and P-ALBI 1 and 2 was 26.7 vs. 8.6 months ( P < 0.001). In multivariate analyses, both ALBI 2 (HR = 2.4, P = 0.02) and P-ALBI 2 (HR = 3.3, P < 0.01) were negative prognostic factors for survival. There were 15 AEs in 13 patients, with hepatic failure only occurring in ALBI 2 and P-ALBI 2 patients. CONCLUSION: P-ALBI grade 1 and 2 differentiated survival in Child-Pugh A patients treated with DEE-TACE. Both grading systems can differentiate survival in patients responding to treatment.


Assuntos
Bilirrubina/sangue , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/métodos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/terapia , Albumina Sérica/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/sangue , Feminino , Humanos , Fígado/metabolismo , Fígado/patologia , Fígado/fisiopatologia , Testes de Função Hepática/métodos , Testes de Função Hepática/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Reprodutibilidade dos Testes , Estudos Retrospectivos , Resultado do Tratamento , Carga Tumoral
2.
Cardiovasc Intervent Radiol ; 38(6): 1532-41, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25832764

RESUMO

PURPOSE: The purpose of this study was to evaluate treatment response and complications of transarterial chemoembolization using drug-eluting beads loaded with irinotecan (DEBIRI) in patients with liver metastases from uveal melanoma (UM). MATERIALS AND METHODS: Patients treated with DEBIRI (n = 14) were retrospectively analyzed regarding overall survival, compared to patients (n = 14) treated with intravenous dacarbazine (DTIC). Median overall survival was calculated from time of diagnosis of metastatic disease (OS1) and start of treatment (OS2). Radiological response for DEBIRI was assessed according to RECIST 1.1 on contrast-enhanced computed tomography (CT), obtained 1.5 months (range 1.2-3.7) post treatment. Major complications of DEBIRI were defined according to the Society of Interventional Radiology classification for complications by outcome. RESULTS: In the DEBIRI group, OS1 was 14.8 months (range 3.9-47.5), and OS2 was 9.4 months (range 1.7-39). Further, 11/13 (84.6%) of these patients had progressive disease on first follow-up CT and new lesions were seen in nine. There were 12 major complications in nine patients, possibly including one case of mortality due to disseminated intravascular coagulation (DIC). CONCLUSION: For patients with liver metastases from UM, the effect on overall survival of DEBIRI alone is questionable. Compared to previous reports, the response rate of DEBIRI was poor, with new liver lesions observed in the majority of patients. Major complications possibly included one case of DIC.


Assuntos
Antineoplásicos Fitogênicos/administração & dosagem , Camptotecina/análogos & derivados , Quimioembolização Terapêutica/métodos , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Melanoma/patologia , Neoplasias Uveais/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos Fitogênicos/efeitos adversos , Camptotecina/administração & dosagem , Camptotecina/efeitos adversos , Quimioembolização Terapêutica/efeitos adversos , Meios de Contraste , Sistemas de Liberação de Medicamentos , Feminino , Humanos , Irinotecano , Fígado/diagnóstico por imagem , Neoplasias Hepáticas/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Intensificação de Imagem Radiográfica , Estudos Retrospectivos , Terapêutica , Tomografia Computadorizada por Raios X , Adulto Jovem
3.
Minim Invasive Ther Allied Technol ; 22(2): 73-9, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22793778

RESUMO

INTRODUCTION: The purpose of this study was to evaluate the feasibility and safety of the Sonalleve high-intensity focused ultrasound (HIFU; Philips Healthcare, Vantaa, Finland) system in ablating uterine fibroids in a 3T magnet. MATERIAL AND METHODS: Seven women were included in this study. Treatment was performed according to the manufacturer's recommendation. Technical data describing the HIFU procedures were collected. On MR images at baseline, immediately and 30 days after ablation, we evaluated the volumes of the uterus, the dominant fibroid and the ablation zone. The Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire was used to assess potential clinical response. RESULTS: The procedure was technically feasible in all patients. The median number of sonications performed during each procedure was 20 (range 2-27) per patient, the maximum temperature in all sonication cells was about 68°C. The median procedure time was 156 minutes (range 95-164). The non-perfused volume after treatment ranged from 1 to 27 ml and was unchanged or decreased in all but one patient at 30 days follow-up. There were no major adverse events. DISCUSSION: In our 3T magnet the system was able to heat tissue and induce areas of non-enhancement within uterine fibroids without major complications. Clinical benefit remains to be proven.


Assuntos
Ablação por Ultrassom Focalizado de Alta Intensidade/métodos , Leiomioma/cirurgia , Imageamento por Ressonância Magnética/métodos , Neoplasias Uterinas/cirurgia , Adulto , Estudos de Viabilidade , Feminino , Seguimentos , Ablação por Ultrassom Focalizado de Alta Intensidade/efeitos adversos , Ablação por Ultrassom Focalizado de Alta Intensidade/instrumentação , Humanos , Leiomioma/patologia , Pessoa de Meia-Idade , Qualidade de Vida , Inquéritos e Questionários , Temperatura , Fatores de Tempo , Resultado do Tratamento , Neoplasias Uterinas/patologia
4.
Acta Radiol ; 53(1): 34-8, 2012 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-22184676

RESUMO

BACKGROUND: In order to achieve sustained symptom control and minimize the risk of recurrence, uterine artery embolization (UAE) should aim at complete infarction of all fibroids. PURPOSE: To retrospectively evaluate the infarction rate of uterine fibroids in patients that had undergone uterine artery embolization (UAE) after the introduction of contrast-enhanced ultrasound (CEUS) during UAE procedures at our institution. MATERIAL AND METHODS: Thirty patients treated with UAE between February 2006 and August 2009 were included. MR images obtained before, at 3 months, and 12 months after the procedure were reviewed. We evaluated volume changes in dominant fibroids as well as the infarction rate of all fibroids in each patient. Clinical results were evaluated by reviewing the medical records. The study was approved by the institutional review board. RESULTS: CEUS was technically successfully performed during the UAE procedure in all patients. In five cases the endpoint of embolization was adjusted based on findings at CEUS. The mean volume shrinkage of dominant fibroids was 39.8% after 3 months and 59.8% after 12 months. There was complete infarction of all fibroid tissue in 97% of patients at 3 months and 96% at 12 months. No major complications were observed. CONCLUSION: After the introduction of CEUS during UAE procedures in our institution, high infarction rates were achieved.


Assuntos
Meios de Contraste , Infarto/prevenção & controle , Leiomioma/diagnóstico por imagem , Leiomioma/cirurgia , Ultrassonografia de Intervenção/métodos , Embolização da Artéria Uterina/métodos , Adulto , Feminino , Gadolínio DTPA , Humanos , Aumento da Imagem/métodos , Infarto/etiologia , Leiomioma/irrigação sanguínea , Leiomioma/complicações , Pessoa de Meia-Idade , Estudos Retrospectivos , Prevenção Secundária , Resultado do Tratamento
5.
Cardiovasc Intervent Radiol ; 30(5): 882-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17450399

RESUMO

PURPOSE: To evaluate the feasibility of using contrast-enhanced ultrasound (CEUS) during uterine artery embolization (UAE) in order to define the correct end-point of embolization with complete devascularization of all fibroids. METHODS: In this prospective study of 10 consecutive women undergoing UAE, CEUS was performed in the angiographic suite during embolization. When the angiographic end-point, defined as the "pruned-tree" appearance of the uterine arteries was reached, CEUS was performed while the angiographic catheters to both uterine arteries were kept in place. The decision whether or not to continue the embolization was based on the findings at CEUS. The results of CEUS were compared with those of contrast-enhanced magnetic resonance imaging (MRI) 1 day as well as 3 months following UAE. RESULTS: CEUS was successfully performed in all women. In 4 cases injection of particles was continued based on the findings at CEUS despite angiographically complete embolization. CEUS imaging at completion of UAE correlated well with the findings at MRI. CONCLUSION: The use of CEUS during UAE is feasible and may increase the quality of UAE.


Assuntos
Embolização Terapêutica , Leiomiomatose/diagnóstico por imagem , Leiomiomatose/terapia , Angiografia por Ressonância Magnética , Ultrassonografia de Intervenção , Neoplasias Uterinas/diagnóstico por imagem , Neoplasias Uterinas/terapia , Adulto , Artérias/diagnóstico por imagem , Artérias/patologia , Estudos de Viabilidade , Feminino , Humanos , Leiomiomatose/irrigação sanguínea , Leiomiomatose/patologia , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento , Neoplasias Uterinas/irrigação sanguínea , Neoplasias Uterinas/patologia
6.
J Vasc Interv Radiol ; 17(6): 1037-41, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16778239

RESUMO

A patient with a ruptured hypogastric aneurysm was treated via an endovascular approach with coils in the outflow vessels and an Amplatzer vascular plug (AVP) in the main trunk. After 4 weeks, the patient was readmitted with a recurrence of rupture of the hypogastric aneurysm caused by recanalization of the AVP. Final occlusion of the hypogastric artery was achieved by placement of a stent-graft and additional coils. In consideration of this experience, it is recommended that additional coils or several AVPs be used and early contrast medium-enhanced computed tomography follow-up be performed.


Assuntos
Aneurisma Roto/etiologia , Aneurisma Roto/terapia , Embolização Terapêutica/efeitos adversos , Estômago/irrigação sanguínea , Idoso de 80 Anos ou mais , Aneurisma Roto/diagnóstico por imagem , Meios de Contraste , Humanos , Masculino , Recidiva , Stents , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...